David A. Siegel Tyra Biosciences, Inc. Transaction History
Two Sigma Advisers, LP
- $46.1 Billion
- Q2 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Tyra Biosciences, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 87,000 shares of TYRA stock, worth $1.3 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
87,000
Previous 50,100
73.65%
Holding current value
$1.3 Million
Previous $465,000
78.92%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding TYRA
# of Institutions
122Shares Held
59.8MCall Options Held
0Put Options Held
0-
Ra Capital Management, L.P. Boston, MA12.2MShares$182 Million2.55% of portfolio
-
Alta Partners Management Company, L.P. Jackson, WY4.08MShares$60.8 Million93.82% of portfolio
-
Nextech Invest Ag4.06MShares$60.4 Million10.51% of portfolio
-
Nextech Invest, Ltd. Zurich, V84.06MShares$60.4 Million7.35% of portfolio
-
Bvf Inc San Francisco, CA3.94MShares$58.8 Million1.48% of portfolio
About Tyra Biosciences, Inc.
- Ticker TYRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,973,600
- Market Cap $625M
- Description
- Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The comp...